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A gene causing autosomal-recessive, nonsyndromic hearing loss,DFNB39, was previouslymapped to an 18Mb interval on chromosome
7q11.22-q21.12.Wemapped an additional 40 consanguineous families segregating nonsyndromic hearing loss to theDFNB39 locus and
reﬁned the obligate interval to 1.2 Mb. The coding regions of all genes in this interval were sequenced, and no missense, nonsense, or
frameshift mutations were found. We sequenced the noncoding sequences of genes, as well as noncoding genes, and found three muta-
tions clustered in intron 4 and exon 5 in the hepatocyte growth factor gene (HGF). Two intron 4 deletions occur in a highly conserved
sequence that is part of the 30 untranslated region of a previously undescribed short isoform of HGF. The third mutation is a silent substi-
tution, and we demonstrate that it affects splicing in vitro. HGF is involved in a wide variety of signaling pathways in many different
tissues, yet these putative regulatory mutations cause a surprisingly speciﬁc phenotype, which is nonsydromic hearing loss. Two mouse
models of Hgf dysregulation, one in which an Hgf transgene is ubiquitously overexpressed and the other a conditional knockout that
deletesHgf from a limited number of tissues, including the cochlea, result in deafness. Overexpression of HGF is associated with progres-
sive degeneration of outer hair cells in the cochlea, whereas cochlear deletion of Hgf is associated with more general dysplasia.Introduction
There are hundreds of genes that, when mutated, cause
hearing impairment.1–6 The completion of the Human
Genome Project has greatly facilitated the identiﬁcation
of the causative mutations in these genes, especially those
that have been positionally mapped by genetic linkage
studies. When hearing impairment occurs as part of
a genetic syndrome, candidate genes can usually be identi-
ﬁed on the basis of a hypothesized function consistentwith
the physiological effects of the syndrome or by the correla-
tion of expression pattern of the candidate gene with the
tissues affected in the syndrome.2,7 But in the case of non-
syndromichearing impairment (NSHI), thegenes identiﬁed
so far have shown such wide diversity of function and
expression patterns that it is difﬁcult to predict which
gene in a linkage interval would be the best candidate.8,9
Of the ~105 NSHI loci that have been mapped thus far,
the causative mutation has been identiﬁed in 47 genes
(Hereditary Hearing Loss homepage). These vary from
cochlear-speciﬁc genes with functions specialized to the
inner ear (e.g., OTOA [MIM 607038]10) to nearly ubiqui-
tously expressed genes with presumed housekeeping
functions (e.g., ACTG1 [MIM 102560]11,12). Given theseThprecedents, researchers are left little alternative but to
systematically sequence every gene in a linkage interval
for a DFNA (dominantly inherited) or DFNB (recessively in-
herited) NSHI locus.
It is inevitable that for some DFNA or DFNB loci, no
mutation in the coding sequences of any gene in the
linked interval would be found. This follows by extrapola-
tion from the few cases of well-deﬁned monogenic
disorders in which comprehensive analyses have revealed
mutations in the noncoding regions of the gene. For
example, there are 536mutant alleles of theHBB (b-globin)
gene (MIM 141900), and over 11% of them (61) are in non-
coding sequences. These include mutations of 50 untrans-
lated regions (UTRs), 30 UTRs, and introns and are hypoth-
esized to affect regulation of HBB. But it is the occurrence
of these mutations that deﬁnes these sequences as candi-
dates for regulation of HBB, because regulatory sequences
are difﬁcult to predict from sequence information alone.
Almost all regulatory mutations are identiﬁed only after
the exclusion of mutation in the coding sequences of
a gene with a well-established correlation to a speciﬁc
phenotype.13,14 The identiﬁcation of a disease gene
through mutations in its putative regulatory sequences is
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Here, we report the results of a mutation screen for the
autosomal-recessive NSHI locus DFNB39 (MIM 608265).15
The linkage interval, with boundaries deﬁned by recombi-
nations in families that support highly signiﬁcant LOD
scores, was reﬁned. We examined the coding sequences
of every gene in the interval, as well as many noncoding
sequences. We found three mutations in HGF, the gene en-
coding hepatocyte growth factor (MIM 142409). None of
the mutations cause amino acid replacements. Two of the
mutations occur in a region that we demonstrate to be con-
tained in the 30 UTR of an alternate splice form of HGF that
to our knowledge has not been previously discovered.
Additionally, evidence is provided that the third mutation,
which is a third-position nucleotide change predicted to
make a synonymous amino acid substitution, alters
splicing by affecting the relative strengths of the splice
acceptor sites in two known alternate splice forms of
HGF. The NSHI phenotype of this widely expressed, and
widely studied, gene will offer an opportunity for gaining
insight on HGF regulation in general and its regulation
and function in the cochlea in particular.
Subjects and Methods
Family Enrollment and Diagnosis
Consanguineous families with probands enrolled in schools for
the deaf were ascertained in Pakistan and India. Written informed
consent was collected from all participants after approval was ob-
tained from the Combined Neuroscience Institutional Review
Board (IRB) at the National Institutes of Health (NIH), Bethesda,
MD, USA; the IRB at Baylor College of Medicine, Houston, TX,
USA; the IRB at the National Centre of Excellence in Molecular
Biology, Lahore, Pakistan; the IRB at Quaid-I-Azam University, Is-
lamabad, Pakistan; and the IRB at the All India Institute of Medical
Sciences, New Delhi, India. Participating hearing-impaired indi-
viduals were evaluated bymedical-history interviews and a general
physical examination. At least two hearing impaired individuals
from each family underwent pure-tone audiological assessment.
Some individuals were evaluated by funduscopy, serum chemistry,
CBC, and urine analysis for ruling out features of a syndrome.
Peripheral blood samples were obtained from each participating
individual, and genomic DNA was extracted.16
Linkage Analysis
The DFNB39 locus was deﬁned at 7q11.22-q21.12 by a genome-
wide linkage screen of family DEM4011.15 Seventeen additional
families were found to segregate recessive deafness linked to
DFNB39 in genome-wide linkage scans. Eleven of the families
were mapped with the use of ~400 microsatellite markers with
an average resolution of 10 cM from the Marshﬁeld map,17 and
six were mapped with the use of Illumina genome scan SNP
marker loci panels with an average resolution of 1.5 cM (Table 1).
An additional 23 families were found to be segregating the
DFNB39 gene either by screening for linkage to the known
DFNB loci with the use of a panel of STR markers (Hereditary
Hearing Loss homepage) or by screening for mutations in HGF.
Once linkage to the DFNB39 locus was established for these
families, no further genetic linkage analyses were performed on
them.26 The American Journal of Human Genetics 85, 25–39, July 10, 200LOD scores for the families labeled with a PK, IDM, or Kla preﬁx
were calculated in MLINK of the FASTLINK computer package.18
LOD scores for the families labeled with the DEM preﬁx were
calculated in MLINK, used for two-point analyses, and with
ALLEGRO19 and SIMWALK2, used for multipoint analyses.20,21
Marker allele frequencies were estimated with genotypes from
founders and reconstructed founders from the DEM pedigrees.
Haplotypes were reconstructed in ALLEGRO and SIMWALK2.
Candidate Gene Screening
Candidate genes within the DFNB39 interval were screened for
mutations by direct sequencing of PCR products generated from
genomic DNA from one affected individual of some DFNB39-
linked families. Regions of conservation were identiﬁed with the
Vertebrate Multiz Alignment and PhastCons Conservation (28
species) track of the UCSC Human Genome browser. Primers
were designed with Primer3 software for ampliﬁcation of all exons
of each candidate gene, including the intron-exon boundaries.
Primer pairs for HGF are listed in Table S1, available online.
Methods for direct sequencing of PCR products were described
previously.22 BigDye terminator reaction products were resolved
on ABI377 or ABI3730 instruments. Sequencing traces were
analyzed with the Phred, Phrap, and Consed software suite, and
mutations were identiﬁed with the aid of Polyphred.23–25
Cosegregation of the mutation with deafness in each family was
conﬁrmed by direct sequencing of PCR products ampliﬁed from
genomic DNA of all participating family members. Control DNA
samples from Pakistan and India were analyzed for putative muta-
tions, as were Caucasian control samples (HD200CAU) and pan-
ethnic control samples (HD01-09, HD27) from the Human Diver-
sity Panel (Coriell Cell Repositories, NJ, USA) (Table S2).
In Vitro Splicing Assay
The effect of each of the three mutations on splicing of HGF was
evaluated by an exon trapping assay.26 A PCR fragment encom-
passing exons 4 and 5 of HGF was ampliﬁed from genomic DNA
of a noncarrier from family PKDF402 (wild-type) and an affected
individual from each of three families, PKDF402 (c.482þ
1986_1988delTGA), PKDF601 (c.482þ1991_2000delGATGATGA
AA), and PKDF210 (c.495G>A), with the primer pair 50-CTGCA
GGGTTGTCCTATCAGCAGTGGA-30 and 50-CTGCAGGAAGCAG
GTGCTGGTTGAAT-30. The HGF cDNA numbering is in reference
to the ‘‘A’’ of the ATG start site of RefSeq No. NM_000601.
Each of the four 6.0 kb genomic DNA fragments were cloned
into pSPL3 (GIBCOBRL), sequence veriﬁed, and transfected into
COS-7 cells with Lipofectamine 2000 (Invitrogen). After 24 hr,
total RNA was extracted from the transfected cells with the use
of Trizol (Invitrogen) and cDNA was synthesized with Superscript
III RT (Invitrogen) with the use of oligonucleotide SA2 50-ATCT
CAGTGGTATTTGTGAGC-30. Primary and nested secondary PCR
ampliﬁcations of the cDNA were performed with vector-speciﬁc
primers, and products from the nested PCR were subcloned
and sequence veriﬁed as recommended (Exon Trapping Kit,
GIBCOBRL). The numbers given in Table 2 are the totals of four
independent experiments for each allele. Contingency table prob-
abilities were calculated with Prism 5 software (GraphPad).
Hgf Conditional Knockout and Transgenic Mice
Mice with loxP sites ﬂanking exon 5 of theHgf gene (HGFex.5-ﬂox)27
were used for the creation of an inner ear conditional knockout of
Hgf. Homozygous Hgf ﬂoxed mice were bred to heterozygous Hgf9
Table 1. Summary of DFNB39 Families
Family IDa Genome Scan Method LOD Scoreb Mutationc
PKDF002d,e STR 4.27 D3
PKDF084d,e SNP 6.11 D3
PKDF121d,e - 4.00 D3
PKDF157d,e - 7.03 D3
PKDF204d,e - 4.80 D3
PKDF239e,f - 7.41 D3
PKDF351e,f - 5.34 D3
PKDF352e - 3.35 D3
PKDF402e - 4.16 D3
PKDF711e - 2.20 D3
PKDF841e - 2.89 D3
PKDF847 - 2.15 D3
PKDF879 - 3.24 D3
PKDF1113 - 12.00 D3
PKSR36ad,e - 1.84 D3
PKSR53ad,e - 3.22 D3
PKSR2bd,e - 3.52 D3
IDM13d,e - 3.15 D3
Kla2d,e - 2.33 D3
DEM4011e STR 3.7 D3
DEM4017A STR 3.1 D3
DEM4018e STR 6.03 D3
DEM4048 STR 3.02 D3
DEM4050 STR 1.93 D3
DEM4058 STR 2.37 D3
DEM4071 STR 5.75 D3
DEM4142e STR 2.53 D3
DEM4174e STR 3.54 D3
DEM4199e STR 3.73 D3
DEM4201 SNP 2.3 D3
DEM4212 STR 1.35 D3
DEM4320 SNP 1.93 D3
DEM4332 SNP 1.93 D3
DEM4333A SNP 1.33 D3
DEM4333B SNP 1.86 D3
DEM4434 - 6.57 D3
DEM4443 - 3.14 D3
DEM4467 - 2.53 D3
DEM4472 - 3.61 D10
PKDF601e - 4.22 D10
PKDF210d,e - 2.38 c.495G/ATheﬂoxed mice also segregating the cre recombinase gene under the
control of the endogenous Foxg1 gene promoter [B6.129P2(Cg)-
Foxg1tm1(cre)Skm/J] (The Jackson Laboratory).28 Wild-type (1.1 kb)
and ﬂoxed (1.4 kb) exon 5 Hgf alleles were detected in genomic
DNA from mouse tails by PCR ampliﬁcation with the primer
pair 50-TGTGACCCTGGATCATCAGTGTAA-30 and 50-GCTGATT
TAATCCCATTTCTTCA-30. The presence of the cre gene was de-
tected in genomic DNA from mouse tails by PCR ampliﬁcation
with the cre-speciﬁc primer pair (358 bp amplimer) 50-ACGACC
AAGTGACAGCAATG-30 and 50-CCATCGCTCGACCAGTTTAG-30.
The generation of MH19 transgenic mice overexpressing full-
length Hgf cDNA was previously described.29 The Hgf transgene
was detected by PCR ampliﬁcation of a 550 bp product from
mouse tail genomic DNA with the primer pair 50-TCTCGTAAA
CTCCAGAGC-30 and 50-GGGTCTTCCTTGGTAAG-30. All animal
procedures were approved and conducted according to the NIH
Animal Care and Use Committee guidelines and Animal Protocols
1263-06 and 08-049 (to T.B.F. and G.M., respectively).
Phenotypic Evaluation of Mice
Mice were anesthetized with an intraperitoneal injection of
a mixture of 100 mg/ml ketamine hydrochloride (42–56 mg/kg
body weight) and 1 mg/ml medetomidine hydrochloride (0.56–
0.75 mg/kg body weight) and placed on a heating pad in
a All families except Indian families IDM13 and Kla2 were ascertained in
Pakistan.
b Maximum two-point LOD score obtained at q ¼ 0.
c D3 ¼ c.482þ1986_1988delTGA; D10 ¼ c.482þ1991_2000delGATGATG
AAA.
d DNA from families sequenced for 374 amplicons in the DFNB39 linkage
region.
e DNA from families sequenced for all coding and conserved noncoding
sequences of HGF.
f Pedigrees that define the proximal and distal breakpoints for the minimal
DFNB39 interval.





Clones c2 p Value
Wild-Type 5a 33/63 NA NA
Wild-Type 5b 26/63 NA NA
Wild-Type otherb 4/63 NA NA
D3 5a 23/47 0.673 0.71
D3 5b 19/47 0.673 0.71
D3 otherb 5/47 0.673 0.71
D10 5a 20/37 0.184 0.912
D10 5b 14/37 0.184 0.912
D10 otherb 3/37 0.184 0.912
c.495G/A (p.S165S) 5a 0/39 31.69 0.0001
c.495G/A (p.S165S) 5b 37/39 31.69 0.0001
c.495G/A (p.S165S) otherb 2/39 31.69 0.0001
NA denotes ‘‘not applicable.’’
a D3 ¼ c.482þ1986_1988delTGA; D10 ¼ c.482þ1991_2000delGATGATG
AAA.
b A few aberrant splicing products were identified for each allele that skipped
exon 4, exon 5, or both exons 4 and 5. These are presumed to be artifacts and
are listed as ‘‘other.’’American Journal of Human Genetics 85, 25–39, July 10, 2009 27
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Figure 1. Four of 41 Families Segregating Mutant Alleles of HGF Associated with Deafness
(A) Filled symbols of pedigrees represent individuals with prelingual, severe to profound hearing loss, and a double horizontal line indi-
cates a consanguineous marriage. Numbers below individual symbols indicate that the person was enrolled in the study and that their
DNA sample was genotyped. Haplotype data for families PKDF239 and PKDF351 indicate the smallest linkage interval. The deafness in28 The American Journal of Human Genetics 85, 25–39, July 10, 2009
a sound-attenuated booth (Acoustic Systems). Auditory-evoked
brainstem responses (ABRs) were measured with TDT System 3
hardware and software (Tucker-Davis Technologies) with free-ﬁeld
presentation of auditory stimuli through an ES1 electrostatic
speaker. Clicks and pure-tone pips were presented as 3msec bursts,
with 1 msec rise and fall times at 21 stimuli/sec. The recorded ABR
at each presentation level was a cumulative average from a
minimum of 500 stimuli. After testing, the animals were adminis-
tered 5 mg/ml Antisedan (2.75–3.67 mg/kg body weight) and al-
lowed to recover from anesthesia in a warm cage. Effects of
genotype and age on ABR thresholds were analyzed by two-way
ANOVA with Prism 5 software (GraphPad). Distortion product
otoacoustic emissions (DPOAEs) were recorded with DP2000
measurement software, version 3.0 (Starkey Laboratory), and an
ER-10C acoustic probe (Etymotic Research). The DP (2f1f2)
amplitudes from both ears were averaged for each mouse.
Six conditional knockout mice (Hgf Fl/Fl; Foxg1cre/þ) (three males,
three females) and six littermate controls (Hgf Fl/þ; Foxg1cre/þ) (ﬁve
males, one female) were evaluated at 7–8 wks of age by the Mouse
Phenotyping Service, Division of Veterinary Resources, NIH. Mice
were sacriﬁced with CO2 asphyxiation and necropsied. Mouse
tissues were harvested and ﬁxed in 10% formalin, processed with
alcohols and xylenes, embedded in parafﬁn, sectioned at 5
microns, stained with hematoxylin and eosin, and visualized by
light microscopy.
Fluorescence Confocal Microscopy
Inner ears of wild-type and mutant mice were ﬁxed with 4% para-
formaldehyde overnight at 4C and rinsed with phosphate-buff-
ered saline (PBS). The organs of Corti were dissected and incu-
bated overnight at 4C with rhodamine-phalloidin (Molecular
Probes), mounted on glass slides in ProLong Gold antifade reagent
(Invitrogen), and visualized on a Zeiss LSM710 laser confocal
microscope.
Lymphoblastoid Cell Lines and cDNA Synthesis
Lymphoblastoid cell lines were established by the Coriell Cell
Repository via Epstein-Barr-virus transformation of peripheral
blood samples from one affected individual and one carrier indi-
vidual from four DFNB39 families (PKDF002, PKDF084, PKDF121,
and PKSR53a). Cells were grown in RPMI-1640 supplemented
with L-glutamine (GIBCO) and 15% fetal bovine serum (FBS) (At-
lanta Biologicals) at 37C and 5% CO2.
Total RNA was extracted from lymphoblastoid cell cultures with
Trizol (Invitrogen). Poly Aþ RNA was isolated with an Oligotex
mRNA Kit (QIAGEN), and cDNA was synthesized with Superscript
III RT (Invitrogen) with the use of an Oligo(dT) SMART primer
(Clontech). Human brain ﬁrst-strand cDNA was synthesized
from human brain polyAþ RNA (Clontech) with an Oligo(dT)
primer and Powerscript Reverse Transcriptase (Clontech). The
cDNAs were ampliﬁed with the primer pair 50- ATGTGGGTGAC
CAAACTCCT-30 and 50- GGTGGCCAATGAAGGATACA-30.Results
Clinical Findings
Hearing was evaluated by pure-tone audiometry for at least
two affected members (age range 3 to 45 yrs) from each of
the 41 families (Figure 1 and Figure S1). The hearing loss
was prelingual, bilateral, and severe to profound, with
a downward-sloping audiometric conﬁguration. Bone con-
duction threshold testing in some individuals conﬁrmed
a sensorineural etiology, but we cannot formally rule out
a mixed hearing loss in others. Some affected individuals
from families PKDF210 and PKDF601 segregate a slightly
milder phenotype characterized by moderately severe
hearing loss at low frequencies.
General physical examination of affected individuals
and retinal fundus examination of two affected individuals
from family PKDF121 (24 and 28 years old) and two from
PKDF879 (28 and 45 years old) ruled out Usher syndrome
and obvious abnormalities in other organ systems. Serum
chemistry, CBC, and urine analysis of two affected and
two unaffected individuals from each of three families,
PKDF121 (age range 24–40 years), PKDF841 (age range
8–15 years), and PKDF847 (age range 10–42 years), did
not identify any abnormalities consistent among affected
individuals. The clinical data for these families suggests
a nonsyndromic, severe to profound hearing loss.
Genetic and Physical Map
DFNB39 was originally mapped to 7q11.22-q21.12 by
genome-wide linkage analysis of family DEM4011.15 We
report an additional 40 families with severe to profound
deafness that cosegregates with markers at the DFNB39
locus. Additional Pakistani and Indian families segregating
profound, prelingual, recessive deafness were screened for
linkage to markers at all of the currently known DFNB loci
(Hereditary Hearing Loss homepage). Deafness segregating
in 19 families was linked to DFNB39 with LOD scores
greater than the 3.3 threshold for signiﬁcance.30,31 In 22
families, deafness cosegregates with the DFNB39 locus,
but these families are too small to support LOD scores
greater than 3.3 (Table 1, Figure 1, and Figure S1). With
the assumption of genetic homogeneity at this locus,
a total of 41 DFNB39 families were ascertained.
The minimal linkage interval of DFNB39 was deﬁned by
families that independently support highly signiﬁcant
evidence for linkage: PKDF239 (LOD 7.41, D7S3329) and
PKDF351 (LOD 5.34, D7S3328) (Figure 1). Inspection of
the haplotypes segregating in these families revealsPKDF239 and PKDF351 cosegregates with c.482þ1986_1988delTGA (D3). Only informative markers are shown for the sibships that
deﬁne the genetic breakpoints. The proximal breakpoint (arrowhead) is deﬁned by individual 27 of family PKDF239 at SNP
rs3215357. The distal breakpoint (arrow) is deﬁned by individuals 35 and 36 of family PKDF351 at SNP rs1229497, located between
HGF and CACNA2D1. The deafness phenotype of family PKDF601 cosegregates with c.482þ1991_2000delGATGATGAAA (D10) in
intron 4 of HGF. The deafness phenotype of family PKDF210 cosegregates with c.495G>A (p.S165S) in HGF.
(B) Representative nucleotide sequence chromatograms of intron 4 of HGF showing the wild-type, homozygosity for the 3 bp deletion,
and homozygosity for the 10 bp deletion.
(C) Wild-type and homozygous mutant nucleotide sequence chromatograms of exon 5 of HGF, illustrating homozygosity for the
c.495G>A (p.S165S) mutation (arrow) and the 5a (underlined) and 5b (double underlined) splice acceptor sites.
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a proximal meiotic breakpoint between SNP rs3215357
and STR marker D7S3330 in PKDF239 (arrowhead,
Figure 1A) and a distal meiotic breakpoint between STR
marker D7S3328 and SNP rs1229497 in PKDF351 (arrow,
Figure 1A). The interval between rs3215357 and
rs1229497 comprises 1.187 Mb at 7q21.11 (NCBI build
36.1) and is entirely within the original 18 Mb DFNB39
locus.15
Identiﬁcation of DFNB39
Genes inor just outside the smallest linkage interval include
CLDN3, CLDN4, MAGI2, GNAI1, GNAT3, CD36, SEMA3C,
HGF, CACNA2D1, PCLO, SEMA3E, SEMA3A, and CLDN12
(Figure 2A). We sequenced all of the coding exons, in-
cluding splice sites and ~50 bp of ﬂanking intronic
sequence, in each of these genes in affected individuals
from11DFNB39-linked families. In addition, conserved in-
tronic sequences and DNA corresponding to transcripts of
unknown function were sequenced, including mRNAs
AY927633 and AY927634 (Unigene Hs.571267) because
their small open reading frames have similarity to cadherin
ectodomains.32 A total of 374 ampliconswere sequenced in
a subset of 11DFNB39-linked families (families indicated in
Table 1). Because the41 familieswere enrolled inour respec-
tive studies over a period of several years, some of the
DFNB39 families were evaluated for only a subset of the
374 amplicons.Nomissense, nonsense, or frameshiftmuta-
tions were identiﬁed in the coding sequences of any of the
genes in this interval. However, we did ﬁnd three potential
regulatory mutations in the HGF gene.
A transitionmutation inHGF resulting in a synonymous
substitution (c.495G>A [p.S165S]) cosegregates with deaf-
ness in family PKDF210 (maximum LOD score of 2.38)
(Figures 1A and1C). ThisG-to-A transitionmutation occurs
13 nucleotides into exon 5 relative to the exon 5a splice
acceptor site of HGF isoform 1 (RefSeq no. NM_000601),
but at the minus 3 position (c.483-3G>A) relative to the
exon 5b splice acceptor site of HGF isoform 3 (RefSeq no.
NM_001010932) (Figures 1C and 2B). This nucleotide
substitution is predicted to alter the relative strengths of
these two splice acceptor sites. For example, Genscan33predicts exon 5 with the 5a acceptor site and a probability
(P) of 0.682 when given the c.495G wild-type sequence as
input, but prefers the 5b acceptor site with p ¼ 0.592
when the c.495A mutation sequence is given as input.
The c.495G>A transition was not found among 1040 chro-
mosomes from the Pakistani controls, Caucasian controls,
and Human Diversity Panel controls (Table S2), nor was it
found in the dbSNP database.
We sequenced intragenic and intergenic regions of the
DFNB39 interval that were highly conserved among
species, including a 500 bp region of intron 4 of HGF that
is 79% identical to the corresponding mouse sequence
(Figure 2C). By comparison, the coding sequences of
human HGF andmouse Hgf are 88% identical. This intronic
region is transcribed in mice as part of the 30 UTR of a short
isoform of Hgf (RefSeq no. AK082461). We subsequently
determined that this region is also transcribed in humans
as part of the 30 UTR of a previously uncharacterized short
HGF isoform (Figure 2B). We identiﬁed a 3 nt deletion in
intron 4 (c.482þ1986_1988delTGA) that cosegregates with
deafness in 36 Pakistani and two Indian families (Figures
1Aand1B,FigureS1).A10bpdeletion(c.482þ1991_2000del
GATGATGAAA), located in intron 4 of HGF, adjacent to the
3 bp deletion, cosegregates with deafness in families
PKDF601 and DEM4472 (LOD 4.22 and 3.61, respectively)
(Figure 1A and Figure S1). This 10 bp sequence is tandemly
duplicated in humans, the ﬁrst duplication encompassing
the 3 bp deletion as well (solid blue lines, Figure 2D). These
duplications are also part of a stretch of 21 overlapping
6 bp exon splice enhancer sites predicted by the Rescue-ESE
program (black dashed line, Figure 2D).34
Heterozygosity for the 3 bp deletion, c.482þ
1986_1988delTGA, was identiﬁed in 2 of 429 representa-
tive samples from unaffected Pakistani individuals (858
control chromosomes), but was not found in a total of
830 Caucasian, Indian, or Human Diversity Panel control
chromosomes (Table S2). No carriers of the 10 bp deletion,
c.482þ1991_2000delGATGATGAAA, were found among
1688 control chromosomes.
We genotyped seven SNPs in 35 DFNB39 families that
share the same c.482þ1986_1988delTGA deletion in orderFigure 2. DFNB39 Locus, HGF Genomic Structure, Transcripts of HGF, and Intron 4 Sequence Conservation
(A) The linkage intervals for families DEM4011 and PKDF002, which deﬁned the DFNB39 locus, and families PKDF239 and PKDF351,
which deﬁne the smallest linkage interval, are shown as thick horizontal lines with Xs at the proximal and distal recombination sites.
Relative locations and orientations of the genes and mRNAs are indicated with arrows.
(B) Exon structure of the Refseq splice isoforms of HGF and a magniﬁcation of the mutation region. Coding sequences are shaded black,
50 and 30 UTRs are shaded gray. Two previously unpublished transcripts (FJ830861 and FJ830862) are depicted with arrows indicating the
location of the reverse PCR primer site. The forward primer (not shown) was located at the ATG site within exon 1. The 3 bp and 10 bp
deletions are shown as a Dwithin intron 4 and in the 30 UTRs of these two isoforms. Double arrowheads indicate the primer locations for
ampliﬁcation of genomic DNA for in vitro splicing assays.
(C) Nucleotide conservation greater than 75% (100 bp window) between human and mouse genomic DNA viewed with the Vista
Genome Browser. Conserved nucleotide sequences (pink); coding sequences (blue); UTRs of RefSeq isoforms (light blue).
(D) Nucleotide identity (gray shading) in intron 4 of HGF among placental mammals. The 3 bp (c.482þ1986_1988delTGA) and 10 bp
(c.482þ1991_2000delGATGATGAAA) deletions are underlined and boxed in red, respectively. Solid blue bars represent tandemly
repeated 10 bp sequences, one of which is deleted in family PKDF601. Note that the 3 bp and 10 bp deletions can be described as over-
lapping, but are depicted as adjacent to each other in order to conform to the nomenclature guidelines requiring that the nucleotide
number designation begin at the ﬁrst unambiguous occurrence of the deletion. The dotted green bar represents an SRP40 binding
site (predicted by ESE Finder v3, score¼ 4.19). A black dashed line represents a region of 22 overlapping predicted exonic splice enhancer
hexamer sites identiﬁed by Rescue-ESE.
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to evaluate the haplotype of the 221,150 bp region (Table
S3). All of the families with the 3 bp deletion share the
same homozygous haplotype, which consisted of SNPs
rs5745752, rs2286194, and rs1558001. HapMap data
show that this haplotype is found among 15% of Euro-
peans and 11% of East Asians. Although the frequency of
this haplotype in the Pakistani and Indian populations is
not known, the 3 bp deletion is not on a rare haplotype
found only in the Indian subcontinent.
c.495G>A Alters Splicing of HGF Exon 5
Given the predicted effect of the c.495G>A mutation on
splicing at the exon 5a and 5b acceptor sites, as well as
the proximity of the intron 4 deletions to exon 5 of HGF,
we performed in vitro splicing assays to determine whether
any of the three mutant alleles affected splicing of exons
4, 5a, or 5b of HGF (Table 2). With the wild-type construct,
we recovered cDNA clones using the 5a or 5b splice
acceptor sites in roughly equal amounts: 52% and 41%,
respectively. Seven percent of the clones skipped exon 5
or represented other splicing events. The proportion of
these other splicing events did not change signiﬁcantly
among experiments and therefore were considered
aberrant. There was no signiﬁcant alteration of the propor-
tion of 5a and 5b cDNA clones recovered in experiments
using a construct with the 3 bp deletion (49% 5a and
40% 5b) (c2 ¼ 0.673, p value ¼ 0.71) or a construct with
the 10 bp deletion (54% 5a and 38% 5b) (c2 ¼ 0.184,
p value ¼ 0.91). However, the in vitro splicing assay
using a construct with the c.495G>A transition produced
clones with the exon 5b splice acceptor site exclusively
(0% 5a and 95% 5b), thus altering the ratio of isoforms
of HGF containing exons 5a and 5b (c2 ¼ 31.69, p value ¼
0.0001).
HGF and Hgf Isoforms
There are multiple isoforms transcribed at the HGF locus
(Figure 2B). Full-length HGF isoform 1 (NM_000601)
encodes a preprotein that is cleaved into alpha and beta
chains.35 The alpha chain is composed of a hairpin loop
homologous to the plasminogen-activation peptide, fol-
lowed by four N-terminal kringle domains, which are
cysteine-rich motifs involved in protein-protein interac-
tions. The beta chain has homology to trypsin-like serine
proteases but has no catalytic function. After cleavage,
the alpha and beta chains form a heterodimer via disulﬁde
bonds.36 Isoform 2 (NM_001010931) encodes only two
kringle domains (NK2). Isoforms 3 (NM_001010932) and
4 (NM_001010933) are similar to isoforms 1 and 2, respec-
tively, differing only in the usage of the alternate exon 5b
splice acceptor site. A ﬁfth isoform (NM_001010934), en-
coding a single kringle domain (NK1), utilizes the 5a
acceptor site (Figure 2B).
The UCSC Genome Browser annotation of the mouse
Hgf locus (mm9, NCBI build 37) shows orthologs of iso-
forms 1, 3, and 5, as well an mRNA (AK082461) that
ends with a 30 UTR located in intron 4. The open reading32 The American Journal of Human Genetics 85, 25–39, July 10, 200frame of this isoform is predicted to encounter a stop
codon at the beginning of intron 4 and encode no addi-
tional amino acids beyond exon 4. The 30 UTR of this short
isoform includes the region conserved with humans en-
compassing the 3 bp and 10 bp deletions. By RT-PCR, we
were able to demonstrate that mRNAs homologous to
this short mouse isoform are transcribed in human brain
and lymphoblastoid cell lines from individuals who are
homozygous for the 3 bp deletion, as well as from hetero-
zygous and wild-type individuals (FJ830862) (Figure 2B).
We also recovered cDNA clones that show utilization of
the splice donor site for exon 4 and a splice acceptor site
in intron 4 that results in a 30 UTR that encompasses the
region of the 3 bp and 10 bp deletions (FJ830861). This
transcript is predicted to encode 24 additional amino acids
before encountering a stop codon.
Evaluation of Hgf Mutant Mice
In the mouse, homozygosity for mutant alleles of Hgf
causes embryonic lethality in two different knockout-
mouse models.37,38 An allele of Hgf in which exon 5 is
ﬂoxed (Hgf Fl/Fl) was created and used in making a condi-
tional knockout of Hgf in liver tissue, resulting in a viable
mouse with impaired liver-regeneration ability.27 We
used theHgf Fl/Flmouse to generate a conditional knockout
Hgf in the inner ear39 so that we could determine whether
there would be a hearing deﬁcit in the absence of HGF. We
created conditional knockouts by crossing exon 5-ﬂoxed
mice (Hgf Fl/Fl)27 to mice carrying cre driven by the endog-
enous Foxg1 gene promoter (Foxg1cre/þ),28 with subsequent
backcrossing for production of (Hgf Fl/Fl; Foxg1cre/þ) mice. In
the Foxg1cre/þ mouse, cre recombinase expression corre-
sponds to wild-type Foxg1mRNA transcription in the tele-
ncephelon, otic vesicle, optic vesicle, pharyngeal region,
and foregut.28 The Foxg1cre/þ mouse has been used in
generating inner ear knockouts of Bmp4,40 Sox9,41 Tbx1,42
and Fgfr1.43
ABR thresholds were obtained for Hgf conditional
knockout mice at approximately 4 wks and 7 wks of age;
some mice were tested at both ages. There was no differ-
ence in ABR thresholds between the two age groups, and
mice tested at both time points showed no evidence of
progression in their hearing thresholds (data not shown).
The conditional knockout mice (Hgf Fl/Fl; Foxg1cre/þ) dis-
played no response at maximum stimulus levels for 8 kHz,
16 kHz, 32 kHz, and click stimuli, whereas their heterozy-
gous littermate controls with or without cre recombinase
(Hgf Fl/þ; Foxg1cre/þ andHgf Fl/þ; Foxg1þ/þ) displayed normal
ABR thresholds (Figure 3A).
Six conditional knockout mice (Hgf Fl/Fl; Foxg1cre/þ) and
six littermate controls (Hgf Fl/þ; Foxg1cre/þ) were evaluated
by the NIH phenotyping service. There was no signiﬁcant
difference in serum chemistries or CBC between the
mutant mice and littermate controls. The littermate
controls had signiﬁcantly larger body weights and brain
weights than the homozygous mutant mice. Five of the
six mutant mice had dilated and thinned muscular9
AB
CThwalls of the esophagus, which may be a consequence of
Foxg1cre/þ expression in the foregut.28 All six of the mutant
mice had evidence of esophageal reﬂux, leading to aspira-
tion pneumonia in all six and rhinitis in two. Five of the
six mutant mice and one littermate control had otitis
media.
Light microscopy of tissue sections through the inner
ears of Hgf Fl/Fl; Foxg1cre/þ mice revealed morphological
defects not found in littermate controls. The tectorial
membrane appears disorganized in mutant mice as
compared to littermates, and Reissner’s membrane is
collapsed onto the tectorial membrane (Figure 4B). The
stria vascularis appears thin and ﬂattened in mutant mice
(Figure 4C), with occasional clumps of cellular prolifera-
tion (Figure 4B), and the spiral ganglion appears hypo-
plastic. Confocal microscopy shows outer hair cell (OHC)
degeneration throughout the organ of Corti, from base to
apex (Figure 4E).
Having demonstrated that conditional knockout of Hgf
can result in cochlear pathology, we examined an existing
Hgf transgenic mouse model29 to determine whether over-
expression of HGF could affect cochlear function or devel-
opment. MH19-Hgf transgenic mice express ectopic full-
length HGF driven by a metallothionein promoter, with
expression 3- to 50-fold higher than endogenous levels
in all adult tissues tested.29 MH19-Hgf transgenic mice
exhibit ectopic skeletal muscle development and pigment
cells in the central nervous system, patterned hyperpig-
mentation of the dermis and epidermis, tumorigenesis
of mesenchymal and epithelial origin, and frequent
kidney failure and gastrointestinal obstructions.29,44,45
Hearing loss was not reported in the MH19-Hgf transgenic
mice. We tested the hearing of MH19-Hgf transgenic mice
and their littermate controls by ABR and DPOAE and eval-
uated dissections of the inner ears for evidence of
pathology.
Average ABR thresholds of the MH19-Hgf transgenic
mice were 60 dB greater at 8 kHz, 16 kHz, 32 kHz, and
Figure 3. Average ABR Thresholds for Hgf Conditional Knockout
and MH19-Hgf Transgenic Mice and DPOAE Thresholds for
MH19-Hgf Transgenic Mice
(A and B) ABR thresholds in decibels (dB), sound pressure level
(SPL) at 8 kHz, 16 kHz, 32 kHz pure-tone pips, and click stimuli
were measured in Hgf conditional knockout mice and their litter-
mate controls (A) and in MH19-Hgf transgenic mice and their
littermate controls (B). For Hgf Fl/þ; Foxg1þ/þ: n ¼ 21 for pure-
tone pips and n ¼ 13 for clicks. For Hgf Fl/þ; Foxg1cre/þ, n ¼ 11 for
pure-tone pips and n ¼ 8 for clicks. For Hgf Fl/Fl; Foxg1cre/þ, n ¼
10 for pure-tone pips and n ¼ 8 for clicks. Thresholds at all
frequencies were signiﬁcantly different between conditional
knockout mice and littermate controls (p < 0.0001). MH19-Hgf
transgenic mice (n ¼ 4 for 3–5 wks, n ¼ 3 for 6–8 wks) and litter-
mate controls (n ¼ 4 for 3–5 wks; n ¼ 3 for 6–8 wks). Vertical bars
indicate standard deviations. Average ABR thresholds of MH19-
Hgf transgenic mice are signiﬁcantly different from those of their
littermate controls (p < 0.0001).
(C) Mean DPOAEs in MH19-Hgf transgenic mice (n ¼ 13) and
littermate controls (n ¼ 9) at 4–6 wks of age. The mean response
when f2 ¼ 55 dB SPL and f2/f1 ¼ 1.25 is plotted. Vertical bars indi-





Figure 4. Inner Ear Defects in Adult Hgf Conditional Knockout Mice and MH19-Hgf Transgenic Mice
(A) Cross section through themiddle turn of the cochlea of an adultHgf Fl/þ; Foxg1 cre/þmouse shows normalmorphology of the organ of
Corti, Reissner’s membrane (RM), the stria vascularis (SV), and the acellular tectorial membrane (TM).
(B) Cross section of an adult Hgf Fl/Fl; Foxg1 cre/þmutant mouse at the middle turn of the cochlea. Note the hypoplasia of supporting cells
and the hyperplastic clump of cells in the stria vascularis (arrowhead), which otherwise appears thin. The inset shows a higher magni-
ﬁcation of the tectorial membrane, which appears splayed and covered in epithelial cells, presumably derived fromReissner’s membrane,
which is attached to the tectorial membrane.
(C) Another cross section from an adult Hgf Fl/Fl; Foxg1 cre/þ mutant mouse (different than in B), showing the attachment of Reissner’s
membrane to the tectorial membrane (arrow), a clump of hyperproliferative RM cells (arrowhead), and a thin stria vascularis (red arrow).
(D and E) Confocal images of organ of Corti wholemounts stained with phalloidin from a normal Hgf Fl/þ; Foxg1 cre/þmouse (D) and his
Hgf Fl/Fl; Foxg1 cre/þmutant littermate (E). Arrowhead in D indicates the row of normal inner hair cells (IHCs), and arrowsmark three rows
of outer hair cells (OHCs). In E, the IHCs are normal but there are numerous degenerating OHCs, one of which is indicated by an asterisk.
The x-shaped processes that replace OHCs are the borders of neighboring Deiter’s cells.
(F–I) Confocal images of phalloidin-stained wholemounts fromMH19 mice. F shows a region from the middle turn of a wild-type litter-
mate of the animal from which images (G–I) were taken. G is the middle turn of an MH19-Hgf transgenic mouse, showing numerous
degenerating OHCs (example marked by an asterisk), normal IHCs, and a missing pillar cell (arrowhead). Panel H shows a section of
the apex of the cochlea, with essentially normal complement of OHCs, whereas I is a section of the base where virtually every OHC
has degenerated. (Missing IHCs in I are a dissection artifact.)
Scale bars represent 100 mm (A–C), 5 mm (inset, B), and 20 mm (D–I).click stimuli than those of their littermate controls
(Figure 3B). Hearing loss progressed with age in all mice
tested, but most of the hearing loss was attributable to
genotype (Two-way ANOVA results: p < 0.0001 for geno-34 The American Journal of Human Genetics 85, 25–39, July 10, 20type, p ¼ 0.09 for age, and p ¼ 0.45 for interaction of
genotype and age).
A 60 dB threshold shift is consistent with the loss of
cochlear ampliﬁcation as a result of OHC degeneration.4609
OHC function can be assessed by measurement of
DPOAEs, which were signiﬁcantly lower in MH19-Hgf
transgenic mice (Figure 3C). Inspection of organ of Corti
whole mounts via confocal microscopy conﬁrms that
MH19-Hgf transgenic mice display an OHC degeneration
in a spatial gradient, from complete OHC loss at the base
to near-normal complement of OHCs at the apex at
~5 wks of age (Figures 4F–4I). The inner hair cells appear
normal. Cells other than the OHCs appear normal in
inspection of whole mounts via confocal laser microscopy
or of cross sections with light microscopy. No obvious
defects of the tectorial membrane, stria vascularis, Reiss-
ner’s membrane, or supporting cells were observed (data
not shown).
Discussion
HGF was initially identiﬁed as a factor that was secreted
from cultured hepatocytes and acted as a potentmitogen.36
Itwas later shown tobe identical to ‘‘scatter factor,’’which is
secreted from ﬁbroblasts and causes epithelial cells to
disperse in culture.47 Thus, HGF is often referred to in the
literature as HGF/SF. In addition to its properties as both
a mitogen and a motogen, HGF has also been implicated
in branching morphogenesis and invasion,48 tumorigen-
esis,49 erythroid differentiation,50 neuronal survival,51–53
and wound healing.54
The full open reading frame of HGF encodes (from amino
termini to carboxy termini) a signal peptide, an alpha chain
containing four kringle domains, and a beta chain.55 This
inactive pro-HGF polypeptide is converted to the active
form by proteases that cleave between the alpha and beta
chains. The two chains are joined by a disulﬁde bond to
complete the active heterodimer form of HGF. There are
several proteases that can convert pro-HGF to HGF. One of
them, HGF activator (HGFAC [MIM 604552]), is expressed
exclusively in damaged tissue.56 Both the inactive pro-
HGF and HGF can bind the tyrosine kinase MET receptor
(MET [MIM 164860]), but only the active form can stimu-
late downstream pathways through the MET receptor.57,58
The multiplicity of the pathways mediated by MET59 is
one likely reason for the pleiotropic effects inﬂuenced by
HGF. Another, less well characterized, reason for the some-
times paradoxical effects of HGF is the variant forms that
arise as a result of alternative splicing at the HGF locus.
Isoform 1 is the canonical, full-length isoform
(Figure 2B). It is encoded by transcripts that are either
2.8 kb or 6.0 kb in length, depending on the use of alter-
nate polyadenylation sites in the 30 UTR.36 Transcripts
utilizing an alternate exon and polyadenylation site in
intron 7 encode isoform 2, which contains only the amino
terminal through the ﬁrst two kringle domains, and the
protein product is thus referred to as NK2.55,60 Isoform 5,
which contains the amino terminal through only the ﬁrst
kringle domain (NK1), is encoded by transcripts ending in
exon 5 with an alternate 30 UTR and polyadenylationThsignal in intron 5.61,62 Isoforms 3 and 4 are identical to iso-
forms 1 and 2, respectively, except in the usage of an alter-
nate splice acceptor site in exon 5, which results in the
exclusion of ﬁve amino acids from the ﬁrst kringle
domain.63,64 In culture, the NK1 and NK2 isoforms can
exhibit antagonist activity, depending on the cell type ex-
pressing the MET receptor, and so have been proposed as
therapeutic agents to counteract HGF in tumors.60,61
However, transgenic mice expressing NK1 cDNA show
that it can act as a potent agonist,62 and NK2 transgene
expression promotes metastasis, despite inhibiting tumor
growth.65
Almost all of the studies characterizing the differential
effects of HGF, NK1, and NK2 focus exclusively on those
isoforms encoded by the transcripts utilizing the 5a splice
acceptor site. Yet, a functional difference has been demon-
strated for the 5a versus 5b splice acceptor usage. The
exclusion of ﬁve amino acids from the ﬁrst kringle domain
apparently does not affect binding of HGF to MET, but is
thought to alter its ability to bind heparin sulfate proteo-
glycans in the extracellular matrix.66,67 Interaction with
heparin induces NK1, at least, to dimerize, and in turn
causes the MET receptor to dimerize on binding.68,69 The
interaction with heparin and subsequent dimerization
may underlie some of the paradoxical agonist versus antag-
onist properties of NK1.70–72
Other HGF transcripts have been identiﬁed as well,
including those that encode only the beta subunit,73 which
possibly forms ahybrid cytokinewith IL-7.74We reporthere
two additional alternatively spliced transcripts in humans
that include only exons 1–4. The ﬁrst, FJ830861, utilizes
the exon 4 splice donor site and a splice acceptor site within
intron 4. Twenty-four additional amino acids are predicted
to be encoded before reaching a stop codon. The second,
FJ830862, does not splice after exon 4 but reads directly
into intron 4, similar to the short mouse Hgf isoform
AK082461. The open reading frame ends immediately after
the last codonof exon4. Ahighly conserved region of the 30
UTRs of both of these alternate splice forms is partially
deleted in deaf individuals from 40 of our 41DFNB39 fami-
lies. The deletions occur in a region of predicted exonic
splice enhancer sites and adjacent to a predicted splice
factor binding site (Figure 2D, black dashed line and green
dotted line). This suggests that the deletions might cause
dysregulation of one or more HGF isoforms.
Dysregulation of HGF isoforms is also suggested by the
transition mutation c.495G>A (p.S165S). In an in vitro
splicing assay, c.495G>A signiﬁcantly alters the ratio of
HGF splice isoforms that utilize either exon 5a or exon
5b splice acceptor sites. A change in the ratio of 5a versus
5b protein isoforms may decrease heparin binding, which
could inﬂuence whether the isoform acts as a dimer or
a monomer, as mentioned earlier. It could also affect local
HGF sequestration in the extracellular matrix adjacent to
the mesenchymal cells secreting HGF.
The possible effects of HGF dysregulation on HGF-MET-
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especially because the mutations described here most
likely affect smaller isoforms of HGF and the differential
activities of the various isoforms of HGF are not well under-
stood. The primary pathological effect of these regulatory
mutations may be on HGF’s function as a neurotrophic
factor.51,53 In rats exposed to kanamycin, ectopic expres-
sion of human HGF in spiral ganglion cells protected
them against apoptosis and helped maintain normal audi-
tory function.75 Whether endogenous HGF expression
plays a role in protecting the cochlea from ototoxic insult
is unknown. HGF has also been implicated in wound-heal-
ing processes, which may be important in regulating
responses to noise and chemical trauma in the cochlea.76,77
Another possible mechanism for DFNB39-induced
pathology is through the morphogenetic pathways medi-
ated by HGF. In cell culture, one of the genes that is upre-
gulated in response to HGF treatment is SPRY2 (MIM
602466), which in turn acts as a negative feedback regu-
lator of HGF and MET signaling.78 SPRY2 has been impli-
cated in pathways that determine supporting cell fate in
the organ of Corti. A knockout mouse model (Spry2/) is
deaf and exhibits supernumary pillar cells at the expense
of Deiter’s cells.79
These hypotheses of DFNB39-mediated pathology, as
well as other hypotheses, will require an additional mouse
model to test. It is interesting to note that two mouse
models of Hgf dysregulation result in deafness. The condi-
tional deletion of exon 5 of Hgf in the cochlea results in
a profound, nonprogressive hearing loss associated with
extensive morphogenetic pathology, and apparently no
other phenotype. Conversely, the ubiquitous overexpres-
sion of Hgf in a transgenic mouse results in progressive
hearing loss associated with degeneration of the outer
hair cells. The degeneration of hair cells in both types of
Hgf mutant mice is consistent with the general base-to-
apex gradient of development of the cochlea80 and hair
cell degeneration in the mammalian cochlea.81 Although
neither of these mouse models proves HGF is the
DFNB39 gene, they do corroborate the hypothesis that
dysregulation of Hgf isoforms can cause surprisingly
speciﬁc cochlear pathology. A knockin mouse model of
the DFNB39 30 UTR regulatory changes will conﬁrm our
hypothesis. A full evaluation of the relative amounts of
all Hgf isoforms transcribed in the presence and absence
of the mutation can be made only in a mouse knockin
model. Hypotheses concerning which HGF-MET-mediated
pathways are affected will then be tested directly.
Supplemental Data
Supplemental Data include three ﬁgures and three tables and can
be found with this article online at http://www.ajhg.org/.
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